Ensign Peak Advisors
AUPH icon

Ensign Peak Advisors’s Aurinia Pharmaceuticals AUPH Stock Holding History

Ensign Peak Advisors’s Portfolio AUPH Stock Details AUPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$154K Sell
9,085
-1,000
-10% -$16K ﹤0.01% 1489
2026
Q1 		$149K Hold
10,085
– – ﹤0.01% 1447
2025
Q4 		$161K Sell
10,085
-22,750
-69% -$322K ﹤0.01% 1415
2025
Q3 		$363K Sell
32,835
-30,900
-48% -$337K ﹤0.01% 1519
2025
Q2 		$540K Hold
63,735
– – ﹤0.01% 1534
2025
Q1 		$512K Hold
63,735
– – ﹤0.01% 1543
2024
Q4 		$572K Hold
63,735
– – ﹤0.01% 1559
2024
Q3 		$467K Hold
63,735
– – ﹤0.01% 1627
2024
Q2 		$364K Hold
63,735
– – ﹤0.01% 1665
2024
Q1 		$319K Sell
63,735
-3,215
-5% -$21.8K ﹤0.01% 1685
2023
Q4 		$602K Buy
66,950
+17,850
+36% +$147K ﹤0.01% 1620
2023
Q3 		$382K Buy
49,100
+13,650
+39% +$133K ﹤0.01% 1652
2023
Q2 		$343K Buy
+35,450
New +$368K ﹤0.01% 1698
2022
Q4 		– Sell
-40,150
Closed -$302K – 1822
2022
Q3 		$302K Buy
40,150
+7,440
+23% +$64.4K ﹤0.01% 1704
2022
Q2 		$329K Hold
32,710
– – ﹤0.01% 1636
2022
Q1 		$405K Buy
32,710
+1,640
+5% +$25.3K ﹤0.01% 1642
2021
Q4 		$711K Sell
31,070
-100,133
-76% -$2.37M ﹤0.01% 1454
2021
Q3 		$2.9M Sell
131,203
-20,396
-13% -$324K 0.01% 903
2021
Q2 		$1.97M Buy
151,599
+50,540
+50% +$644K ﹤0.01% 1144
2021
Q1 		$1.31M Buy
101,059
+7,702
+8% +$112K ﹤0.01% 1310
2020
Q4 		$1.29M Buy
93,357
+24,832
+36% +$361K ﹤0.01% 1286
2020
Q3 		$1.01M Buy
68,525
+52,872
+338% +$766K ﹤0.01% 1309
2020
Q2 		$254K Buy
+15,653
New +$251K ﹤0.01% 1559

Other funds holding AUPH

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Ensign Peak Advisors's AUPH Position: Q2 2026 in Review

Ensign Peak Advisors reduced its Aurinia Pharmaceuticals (AUPH) stake by 9.9% in Q2 2026, selling an estimated $16K and leaving 9,085 shares worth $154K. The position accounts for ﹤0.01% of the portfolio, ranked #1489.

Ensign Peak Advisors first reported a position in AUPH in Q2 2020 and has held it in 23 quarters since. The position peaked at $2.9M in Q3 2021. 281 funds tracked by Wall St. Rank hold AUPH as of Q2 2026.

  • Ensign Peak Advisors held 9,085 shares of Aurinia Pharmaceuticals worth $154K as of Q2 2026.
  • Ensign Peak Advisors sold 1,000 Aurinia Pharmaceuticals shares in Q2 2026, an estimated $16K.
  • Aurinia Pharmaceuticals made up ﹤0.01% of Ensign Peak Advisors's portfolio in Q2 2026, its #1489 holding.
  • Ensign Peak Advisors first reported a position in Aurinia Pharmaceuticals in Q2 2020 and has held it in 23 quarters since.
  • Ensign Peak Advisors's Aurinia Pharmaceuticals position peaked at $2.9M in Q3 2021.
  • 281 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q2 2026.

Based on Ensign Peak Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.